What is IMNM's current stock price?

IMNM (Immunome, Inc.) is currently trading at $21.66 with a market cap of $2.07B.

What sector is Immunome, Inc. in?

Immunome, Inc. (IMNM) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IMNM a good stock to buy?

Analysts have a Buy consensus on IMNM with a price target of $36.20. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IMNM Immunome, Inc.

Healthcare

$21.66-5.66%ClosedMarket Cap: $2.07B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.16

P/S

515.71

EV/EBITDA

-6.39

DCF Value

$7.38

FCF Yield

-9.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

-1161.9%

Operating Margin

-5947.9%

Net Margin

-5593.8%

ROE

-51.2%

ROA

-36.2%

ROIC

-40.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-53.8M	$—
Q4 null	$0.00	$-69.9M	$—
FY null	$6.9M	$-212.4M	$—
Q3 null	$0.00	$-57.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$36.20

Target (Median)

$36.00

Target Range

$32.00 - $40.00

2 Strong Buy12 Buy0 Hold0 Sell0 Strong Sell

Leerink PartnersOutperform

2026-05-15

HC Wainwright & Co.Buy

2026-05-13

Stephens & Co.Overweight

2026-03-04

Craig-HallumBuy

2026-03-04

WedbushOutperform

2026-01-15

Trading Activity

Insider Trades

View All

BIENAIME JEAN JACQUESdirector

BuyTue May 19

Rosett Maxofficer: Chief Financial Officer

SellFri Apr 03

Rosett Maxofficer: Chief Financial Officer

SellFri Apr 03

Rosett Maxofficer: Chief Financial Officer

SellFri Apr 03

Rosett Maxofficer: Chief Financial Officer

SellFri Apr 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.12

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Peers

UPB